{
  "docId": "019de075-1597-7518-8ef8-7c76bda0fb5f",
  "docSlug": "a75249d5a456b06509b9b61a9aec1423",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 15,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "key_messages",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1597-7518-8ef8-7c76bda0fb5f/3",
  "deckHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f",
  "deckJsonHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f.json",
  "deckAnchorHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.34,
        "x": 0.33,
        "y": 0.25
      },
      "kind": "callout",
      "text": "NOW TWO FDA-APPROVED PRODUCTS",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a02e562-8f90-4506-bd70-c2f88ef52fed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.55,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b975503-061e-4a04-8f72-7e6e14701b01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.15,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "VYVGART (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5744eb6-0646-4149-8ddb-51529569469d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "subtitle",
      "text": "VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9de4d248-7945-4bb6-b222-84f66c9240fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.25,
        "y": 0.05
      },
      "kind": "title",
      "text": "VYVGART for Generalized Myasthenia Gravis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4270014c-0bee-4ae8-af79-8aa37d486d2b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "a2efa267-8ecc-4b5d-9805-1293ed2ee6f7",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Key Messages",
      "beatSlug": null,
      "evidence": "Highlighting VYVGART's role in transforming gMG treatment",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}